How to Get Addyi (Flibanserin) in Arkansas

What Is Addyi and Why Does It Require a Special Conversation With Your Doctor?

Addyi (flibanserin) is the first FDA-approved non-hormonal medication for acquired, generalized HSDD in premenopausal women. It works on serotonin 1A agonism and serotonin 2A antagonism to shift the neurochemical balance between sexual excitation and inhibition in the brain, and it is categorized as a CNS agent rather than a hormone. The FDA granted approval in August 2015 after Sprout Pharmaceuticals demonstrated efficacy in the BEGONIA trial and two additional Phase 3 studies [1][2].

HSDD is defined in the DSM-5 as persistent or recurrent deficiency of sexual desire causing marked distress or interpersonal difficulty, and it is not attributable to another condition or medication effect. Prevalence estimates published by the American College of Obstetricians and Gynecologists suggest that roughly 10% of U.S. women of reproductive age meet diagnostic criteria for the disorder [3]. The condition is distinct from situational low desire or desire differences between partners, a distinction your prescriber will explore before writing the prescription.

Because flibanserin interacts with alcohol to produce hypotension and syncope, the FDA originally required a Risk Evaluation and Mitigation Strategy (REMS) program. The REMS was discontinued in April 2019 after post-marketing data showed the interaction risk was manageable through standard counseling rather than a special certification system [4]. You no longer need to locate a REMS-certified prescriber, which substantially expands access across Arkansas.

In the BEGONIA trial (N=1,585), women who took flibanserin 100 mg nightly reported a statistically significant increase in the number of satisfying sexual events per month compared with placebo, with a mean difference of approximately 0.5 additional events per 28-day period (P<0.001) [1]. Desire scores on the Female Sexual Function Index improved by a mean of 1.0 point versus 0.6 points on placebo.

Arkansas Telehealth Rules and How They Apply to Flibanserin Prescriptions

Arkansas permits telehealth prescribing of flibanserin, and a synchronous audio-video visit satisfies the state's standard-of-care requirement for establishing a valid patient-provider relationship. Arkansas Code Annotated § 17-80-117 defines telehealth and specifies that a prescriber may issue a non-controlled-substance prescription after a real-time video evaluation, provided they are licensed in Arkansas and document the visit in a medical record [5].

Flibanserin is not a controlled substance under the Controlled Substances Act or under Arkansas state scheduling. This makes telehealth prescribing straightforward, as the stricter federal Ryan Haight Act requirements that apply to scheduled medications do not govern flibanserin visits. A provider practicing from Tennessee but holding an Arkansas license, for example, may legally complete your flibanserin visit and send the prescription to an Arkansas pharmacy.

Several national telehealth platforms serve Arkansas patients. HealthRX connects premenopausal women in Arkansas with board-certified OB-GYNs and women's health nurse practitioners for same-week Addyi consultations. The visit typically lasts 20 to 30 minutes and covers symptom duration, ruling out relationship or psychological contributors, medication review for CYP3A4 inhibitors (which are contraindicated with flibanserin), and alcohol use counseling [6].

The FDA label states that "flibanserin is contraindicated in patients using moderate or strong CYP3A4 inhibitors" [2]. Common culprits include fluconazole, clarithromycin, and grapefruit juice. Your prescriber will review your full medication list before writing the prescription. If you take an antifungal or an antibiotic from the macrolide class, a 2-week washout before starting Addyi may be appropriate.

Which Providers in Arkansas Can Prescribe Addyi?

Any licensed prescriber in Arkansas with authority to write outpatient prescriptions for non-controlled substances can prescribe flibanserin. In practice, this includes the following:

Physicians (MD and DO). Arkansas primary care physicians, family medicine doctors, internists, OB-GYNs, and psychiatrists may all prescribe without restriction once they establish a valid clinical relationship.

Nurse practitioners. Arkansas NPs practicing under a collaborative practice agreement with a supervising physician have full prescriptive authority for non-controlled substances, per Arkansas Code § 17-87-310. An NP practicing through a women's health telehealth platform may prescribe Addyi after a compliant video visit.

Physician assistants. PAs in Arkansas prescribe under a delegation agreement with a supervising physician. Non-controlled substances fall within their scope, so a PA at an OBGYN clinic or a telehealth service can write the Addyi prescription [7].

What providers cannot prescribe. Pharmacists practicing under collaborative drug therapy management agreements in Arkansas are limited to drug classes explicitly listed in those agreements, and flibanserin would need to be specified. Dentists and optometrists do not hold authority for HSDD medications.

Across all provider types, the key standard is documentation of HSDD diagnosis using recognized criteria. A one-page checklist covering symptom duration (>6 months), distress level (using a validated scale such as the Female Sexual Distress Scale-Revised), absence of a primary psychiatric or relationship explanation, and confirmation of premenopausal status satisfies most payer and clinical documentation requirements.

Labs and Screening Before Starting Flibanserin in Arkansas

No mandatory lab panel is required by the FDA label before prescribing flibanserin, but Arkansas clinicians following ACOG and ISSWSH (International Society for the Study of Women's Sexual Health) consensus typically order a targeted workup to exclude other causes of low desire [3][8].

Recommended pre-treatment screening includes:

Hormone panel. A morning FSH, estradiol, and total testosterone helps exclude perimenopause (elevated FSH >20 IU/L with low estradiol), primary ovarian insufficiency, or androgen deficiency. Flibanserin is approved only for premenopausal women; a high FSH reading shifts the diagnosis and the treatment approach.

Thyroid-stimulating hormone (TSH). Hypothyroidism suppresses libido. The American Thyroid Association reference range is 0.5 to 4.0 mIU/L. Untreated hypothyroidism should be corrected before attributing low desire to HSDD [9].

Prolactin. Hyperprolactinemia from a pituitary microadenoma or dopamine-blocking medications (antipsychotics, metoclopramide) is a reversible cause of low desire that Addyi will not address.

Comprehensive metabolic panel. Hepatic metabolism is central to flibanserin safety. The FDA label contraindicates Addyi in patients with hepatic impairment because drug exposure increases 4.5-fold in moderate hepatic impairment, raising syncope risk [2]. A basic metabolic panel with liver function tests confirms hepatic competence before prescribing.

Depression screening. The Patient Health Questionnaire-9 (PHQ-9) takes under 3 minutes and catches major depressive disorder, which independently suppresses desire and warrants its own treatment.

Labs can be ordered by your telehealth provider to a national lab network (Quest or LabCorp both operate collection sites throughout Arkansas, including Little Rock, Fayetteville, Fort Smith, and Jonesboro). Results typically return within 48 to 72 hours, allowing a prescription within the same week as the initial consult in most cases.

The HealthRX Arkansas HSDD intake framework sequences screening in three tiers: first, medication and substance review (CYP3A4 inhibitors, alcohol use, SSRIs, antipsychotics); second, hormonal and metabolic labs; third, validated patient-reported outcome scales (FSDS-R, FSFI). Providers complete tier one during the telehealth visit, order tier two labs simultaneously, and score tier three electronically before the prescription is finalized. This three-step sequence reduces unnecessary delays caused by waiting for lab results before even beginning the clinical conversation.

Arkansas Pharmacy Access: Retail, Mail-Order, and 503A Compounding

Retail and mail-order pharmacies. Addyi 100 mg tablets manufactured by Sprout Pharmaceuticals are available at major retail chains operating in Arkansas, including Walgreens, CVS, Walmart Pharmacy, and independent pharmacies that stock specialty women's health medications. Telehealth providers can send the prescription electronically to any Arkansas-licensed pharmacy. Patients in rural counties (e.g., Izard, Stone, or Calhoun County) may find mail-order delivery from an in-network specialty pharmacy faster than a local retail option.

The cash price for a 30-tablet supply (one-month supply at one tablet nightly) runs approximately $800 to $900 without insurance. Sprout Pharmaceuticals offers the "PINK Card" savings program, which reduces the out-of-pocket cost to as low as $99 per month for commercially insured patients and $25 per month for uninsured patients who qualify by income [10].

503A compounding pharmacies. Arkansas-licensed 503A pharmacies may prepare flibanserin for an individual patient based on a valid prescription, provided the compounded preparation is not essentially a copy of the commercially available product. The FDA's current compounding policy under 21 U.S.C. § 503A permits pharmacies to compound drugs that are on the FDA's 503A bulk drug substances list or that meet the "clinical difference" standard [11]. Patients who cannot tolerate an excipient in the branded tablet, or who require a dose different from 100 mg during titration, may be candidates for a compounded formulation. Your prescriber must document the clinical rationale for compounding in the prescription.

Transfer of an existing prescription. If you established care in another state and hold an active Addyi prescription, a licensed Arkansas pharmacy can accept the transfer for non-controlled substances per Arkansas pharmacy board rules. The receiving pharmacist will confirm remaining refills, then dispense from Arkansas inventory or arrange mail delivery.

Arkansas Medicaid and Commercial Insurance Coverage

Arkansas Medicaid covers flibanserin under the pharmacy benefit with limited prior authorization. The PA criteria for Arkansas Medicaid generally require documentation that the patient is premenopausal, has a confirmed HSDD diagnosis, does not have a contraindication to the drug (moderate/strong CYP3A4 inhibitors, hepatic impairment, alcohol use disorder), and has been counseled on the alcohol interaction [12].

Providers submitting a PA for Arkansas Medicaid should include:

1. ICD-10 code F52.0 (hypoactive sexual desire disorder) or N95.1 (menopausal and female climacteric states, if any question of perimenopausal status requires clarification)
2. Clinical notes documenting symptom duration of at least 6 months
3. Documentation of distress using a validated patient-reported outcome measure
4. Confirmation that the patient is not using a prohibited concomitant medication
5. Hepatic function lab results

Most commercial insurers in Arkansas apply similar criteria. Blue Cross Blue Shield of Arkansas, QualChoice, and Arkansas Health and Wellness (a Medicaid managed care organization) each publish preferred drug list criteria that parallel the Medicaid PA checklist. Approval turnaround for PA requests submitted with complete documentation typically runs 3 to 5 business days, though urgent-determination requests can produce a decision within 72 hours under Arkansas Insurance Department rules.

Patients denied coverage can appeal using the same clinical documentation. A written letter from the prescribing provider citing the ISSWSH 2017 consensus recommendations ("pharmacotherapy with flibanserin is supported for acquired, generalized HSDD in premenopausal women when psychological and relationship causes have been excluded") strengthens the appeal record [8].

What to Expect in the First 8 Weeks on Addyi

Flibanserin is dosed once at bedtime, 100 mg, every night. Bedtime dosing is not optional; daytime dosing sharply raises the risk of hypotension, syncope, and sedation because peak plasma concentration occurs approximately 45 minutes after the dose [2]. Taking the tablet at the same time each night, with or without food, minimizes variability.

The FDA label states that patients who do not report meaningful improvement after 8 weeks of consistent nightly use should discontinue the medication, as non-responders are unlikely to benefit from continued treatment. Across the three key trials reviewed in the 2015 approval package, approximately 10% of women discontinued due to adverse effects, with dizziness (11%), somnolence (11%), nausea (10%), and fatigue (9%) as the most common complaints [2].

A 2016 analysis of post-marketing flibanserin data published in the Journal of Sexual Medicine confirmed that the adverse-effect profile seen in clinical trials was reproducible in real-world use, with CNS side effects appearing most frequently in the first 2 to 4 weeks and diminishing for most women who continued past that window [13].

Alcohol is the most clinically significant interaction. The FDA label specifies avoiding alcohol within 2 hours before taking flibanserin and for 8 hours after the dose. Women who drink regularly should discuss their alcohol use honestly during the prescribing visit; this is not a disqualifying factor in most cases, but it requires a clear plan.

Drug interactions to monitor during treatment include moderate CYP3A4 inhibitors (e.g., fluconazole, verapamil, grapefruit juice), strong CYP2C19 inhibitors (e.g., omeprazole, esomeprazole) which raise flibanserin exposure by approximately 24%, and any CNS depressant (benzodiazepines, opioids, sleep aids) that could compound sedation [2][6].

How Long Until Addyi Arrives After a Telehealth Visit in Arkansas?

For patients using a pharmacy in Little Rock, Fayetteville, or another Arkansas city with a Walgreens or CVS, an electronically transmitted prescription can typically be filled the same day or next day. Mail-order pharmacies serving Arkansas generally ship within 24 hours of adjudicating the insurance claim and deliver within 2 to 5 business days via USPS or UPS.

The longest delay in the access timeline is usually prior authorization, which averages 3 to 5 business days for a standard request. Submitting the PA with complete documentation at the time of the visit, rather than waiting for a denial, cuts total time-to-prescription by 4 to 7 days in most cases. HealthRX's clinical coordinators submit PA paperwork on the patient's behalf on the same day as the telehealth visit for patients using Arkansas Medicaid or any commercial plan requiring pre-approval.

Patients using the Sprout PINK Card or paying cash can bypass the insurance process entirely and pick up or receive the drug within 1 to 3 days of the telehealth visit, depending on local pharmacy stock.

Monitoring and Follow-Up After Starting Addyi

Schedule a follow-up appointment at 4 weeks and again at 8 weeks. The 4-week visit evaluates tolerability, confirms no prohibited drug or alcohol interactions have emerged, and checks whether the patient has been able to take the dose consistently at bedtime. The 8-week visit determines whether the patient is a responder.

Response is defined as a clinically meaningful increase in satisfying sexual events, improvement in desire as reported by the patient, and reduction in distress on the FSDS-R. If all three criteria are met and adverse effects are manageable, most providers continue the prescription with quarterly check-ins thereafter. If response is absent at 8 weeks, the standard of care is to discontinue and reassess the diagnosis [2][8].

Periodic liver function checks are not mandated by the label in patients with normal baseline hepatic function, but providers may repeat LFTs annually, especially in patients who drink alcohol occasionally. Thyroid function should be rechecked if new fatigue or weight changes emerge during treatment.